Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
Thursday, March 20, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences has presented promising preclinical safety and efficacy data for PBGENE-HBV, the first clinical stage gene editing therapy targeting chronic hepatitis B. The data supports the safety of repeat dosing, which is crucial for its therapeutic potential. The ELIMINATE-B global Phase 1 study is currently enrolling patients to further evaluate this innovative treatment.
Price reaction · baseline $5.01 (2025-03-19 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
+7%
day 1 · peak
+8.8%
day 3
+1.6%
Market Sentiment Analysis
POSITIVE FACTORS
PBGENE-HBV is the first clinical stage gene editing therapy for chronic hepatitis B.
Preclinical studies show definitive safety and toxicology results.
The ongoing ELIMINATE-B Phase 1 study is actively enrolling patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– PBGENE-HBV, the first and only clinical stage gene editing therapy for chronic hepatitis B – – Repeat dosing of PBGENE-HBV supported by definitive preclinical safety and toxicology studies – – ELIMINATE-B global Phase 1 study for chronic hepatitis B actively enrolling patients and will evaluate
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is the first clinical stage gene editing therapy for chronic hepatitis B.
What studies support PBGENE-HBV's safety?
Definitive preclinical safety and toxicology studies support the safety of PBGENE-HBV.
What is the ELIMINATE-B study?
The ELIMINATE-B study is a global Phase 1 trial evaluating PBGENE-HBV in patients.
Is PBGENE-HBV currently enrolling patients?
Yes, the ELIMINATE-B Phase 1 study is actively enrolling patients.